INFINITI VISION SYSTEM WITH OZIL IP

K082845 · Alcon Research, Ltd. · HQC · Feb 12, 2009 · Ophthalmic

Device Facts

• Record ID: K082845
• Device Name: INFINITI VISION SYSTEM WITH OZIL IP
• Applicant: Alcon Research, Ltd.
• Product Code: HQC · Ophthalmic
• Decision Date: Feb 12, 2009
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 886.4670
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Infiniti® Vision System with OZil® IP is indicated for emulsification and removal of cataracts, vitreous aspiration and cutting associated with anterior vitrectorny, and bipolar coagulation.

Device Story

Infiniti Vision System with OZil IP is a modular phacofragmentation system for ophthalmic surgery. It functions as an enhanced version of the predicate Infiniti Vision System, incorporating the OZil IP feature and the UltraVit Vitrectomy Probe. The system performs cataract emulsification, vitreous aspiration/cutting, and bipolar coagulation. It is used in clinical settings by ophthalmic surgeons. The device processes surgical inputs to provide controlled phacoemulsification and vitrectomy capabilities. Benefits include improved surgical efficiency and control during cataract and anterior segment procedures. The system includes both reusable handpieces and single-use sterile probes.

Clinical Evidence

No clinical data provided. Evidence consists of bench testing, including electrical safety (IEC 60601-1, 60601-1-2, 60601-1-4, 60601-2-2) and biocompatibility evaluations (ISO 10993-1, 5, 7, 10, 11, 12).

Technological Characteristics

Modular phacofragmentation system. Includes OZil IP feature and UltraVit Vitrectomy Probe. Complies with 21 CFR 820 and ISO 14971:2003. Electrical safety per IEC 60601 series. Biocompatibility per ISO 10993 series. Single-use probes sterilized via EtO (ISO 11135:2007). Reusable handpieces processed via validated cleaning/sterilization protocols.

Indications for Use

Indicated for patients requiring cataract surgery (emulsification and removal), anterior vitrectomy (vitreous aspiration and cutting), and bipolar coagulation.

Regulatory Classification

Identification

A phacofragmentation system is an AC-powered device with a fragmenting needle intended for use in cataract surgery to disrupt a cataract with ultrasound and extract the cataract.

Predicate Devices

• Infiniti® Vision System (K021566)
• Sovereign* Cataract Extraction System (K981116)
• Alcon Vision System (Constellation) (K063583)
• Gemini Ophthalmic Surgery System (K911808)

Submission Summary (Full Text)

{0}------------------------------------------------

FEB 12 2009

Infiniti® Vision System with OZU® IP

K082845

Image /page/0/Picture/3 description: The image shows the word "Alcon" in a bold, sans-serif font. The letters are black and slightly pixelated, giving them a textured appearance. The word is horizontally oriented and appears to be a logo or brand name.

## PREMARKET NOTIFICATION 510(k) SUMMARY 5.

This summary document is being prepared in accordance with section 21 CFR 807.92(c).

The submitter of the 510(k) is:

Michael Buenger Associate Director, Regulatory Affairs Alcon Research, Ltd. 6201 South Freeway Fort Worth, TX 76132. Phone: [phone] Fax: [phone]

Device Subject to this 510(k):

Infiniti® Vision System Trade Name: Phacofragmentation System Common Name: Classification Name: Phacofragmentation System (per 21 CFR 886.4670)

#### Predicate Devices : 5.1.

The legally marketed devices(s) to which we are claiming equivalence to are:

| 510(k) Number | Device |
|---------------|-------------------------------------------------------------------------------------------------|
| K021566 | Infiniti® Vision System |
| K981116 | Sovereign* Cataract Extraction System |
| K063583 | Alcon Vision System (Constellation) |
| K911808 | Gemini Ophthalmic Surgery System<br>(Marketed as the Series 20000® Legacy® (STTL) and Accurus®) |

#### 5.2. Device Description

The Infinitie Vision System with OZit® IP is an enhanced version of the Infinitie Vision System (K021566) that is modular in design and incorporates both the QZile IP feature and the Infiniti® UltraVit" Vitrectomy Probe and its associated software.

{1}------------------------------------------------

### Indications for Use: 5.3.

The Infiniti® Vision System with OZil® IP is indicated for emulsification and removal of cataracts, vitreous aspiration and cutting associated with anterior vitrectoriny, and bipolar coagulation.

### Brief Summary of Nonclinical test and Results: 5.4.

Safety tests of the Infinit® Vision System with OZil® IP have demonstrated its compliance with applicable requirements of the following standards:

| Standard | Title |
|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| 60601-1: 2003 UL<br>(Equivalent to IEC 60601-1:<br>1998 with A1: 1991, A2:<br>1995) | Medical Electrical Equipment, Part 1 -- General<br>Requirements for Safety |
| 60601-1-2 :2001 IEC | Medical electrical equipment Part 1: General<br>requirements for safety 2. Collateral Standard:<br>Electromagnetic compatibility-Requirements and test. |
| 60601-1-4:2000 IEC | Medical Electrical Equipment, Part 1: General<br>Requirements for Safety, 4. Collateral standard:<br>Programmable electrical medical systems. |
| 60601-2-2: 1998 IEC | Medical electrical equipment - Part 2-2: Particular<br>requirements for the safety of high frequency surgical<br>equipment |

Biocompatibility evaluations of materials coming in contact with the patient or patient fluid path have been performed to the following standards:

| Standard # | Title |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| 10993-1: 2003 AAMI / ANSI / ISO | Biological Evaluation of Medical Devices --<br>Part 1: Evaluation and testing |
| 10993-5: 1999 AAMI / ANSI / ISO | Biological Evaluation of medical devices --<br>Part 5: Tests for In Vitro cytotoxicity |
| 10993-7: 1995 AAMI / ANSI / ISO | Biological Evaluation of Medical Devices --<br>Part 7: Ethylene Oxide Sterilization Residuals |
| 10993-10:2002/A1:2006 AAMI / ANSI / ISO | Biological Evaluation of Medical Devices --<br>Part 10: Tests for irritation and delayed-type<br>hypersensitivity |
| 10993-11:2006 AAMI / ANSI / ISO | Biological Evaluation of Medical Devices --<br>Part 11: Tests for systemic toxicity |

{2}------------------------------------------------

| | Standard #19 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| | 10993-12:2007 AAMI / ANSI / ISQ Biological Evaluation of Medical Devices -- |
| | Part 12: Sample Preparation and Reference |
| | Materials<br>more forme four leases diving as as a prover a manager was |
| Complete Company Controller of Children Company of Children Company of Children Company of Children Company of Children Company of Children Company of Children Comments of Ch<br>. | and and the contract of the county of the country of the country of the country of |

The Infiniti® UltraVit" Vitrectorry Probe is provided sterile and intended for single use only. This product is EtO sterilized and the process has been validated per AAMV ISO 11135:2007: Medical Devices - Validation and Routine Control of Ethylene Oxide Sterilization. Reusable handpieces are provided non-sterile. Validated reprocessing instructions for cleaning, sterilization and re-use of the handpieces are provided in the Directions for Use of the product.

Technological characteristics affecting clinical performance are similar to that of predicate devices previously listed. The Infiniti® Vision System with OZil® IP has been developed and will be manufactured in compliance with section 21 CFR 820 and ISO 14971:2003. Non-clinical testing noted above has demonstrated that the functional requirements have been met and that the device is equivalent to the predicate device.

Trademark References:

*SOVEREIGN is a registered trademark of Allergan, Inc. Corp.

{3}------------------------------------------------

# DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with its wings spread, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle. The logo is black and white.

## Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Alcon Research, Ltd. c/o Michael Buenger Associate Director, Regulatory Affairs 6201 South Freeway Fort Worth, Texas 76134-2099

FEB 1 2 2009

Re: K082845

Trade/Device Name: Infiniti® Vision System with Ozil® IP Regulation Number: 21 CFR 886.4670 Regulation Name: Phacofragmentation system Regulatory Class: Class II Product Code: HOC Dated: January 12, 2008 Received: January 13, 2008

Dear Mr. Buenger:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{4}------------------------------------------------

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

M. B. Evertins, mD

Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

K082845 / Infiniti Vision System with Ozil IP Response to November 21, 2008 Deficiency Letter

## 4. INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K082845

Device Name: Infiniti® Vision System with OZil® IP

Indications for Use:

The Infiniti® Vision System with OZil® IP is indicated for emulsification and removal of cataracts, vitreous aspiration and cutting associated with anterior vitrectorny, and bipolar coagulation.

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

`Concurrence of CDRH, Office of Device Evaluation (ODE)

HZB histolass

Page 1 of 1

(Division Sign-Off) ovision of Ophthalmic and Ear, Jose and Throat Devices

510(k) Number K082845